A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. - Cherng HJ; Alig SK; Oki Y; Nastoupil LJ; Fayad L; Neelapu SS; Turturro F; Hagemeister F; Craig AFM; Macaulay CW; Rodriguez MA; Lee HJ; et al. (Blood advances, 2023)